Tesofensine can provide the following potential benefits: Appetite suppression Promote weight loss Beneficial effects on learning and memory Enhanced mood Are there side effects
By using this information, you acknowledge responsibility for any decisions made and understand we are not liable for any consequences that may result
(2000), Horm Res 53(Suppl 3), PubMed 10971106 Statistics from preclinical literature AOD-9604 = modified fragment of hGH 177191 + N-terminal Tyr (sequence Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe), molecular weight 1815.1 Da Developed at Metabolic Pharmaceuticals (Australia) based on the work of professor Frank Ng (Monash University) in the 1990s Standard experimental dose in obesity clinical trials: 1 mg/day subcutaneously (Phase 2b, Heffernan et al.) Mechanism: stimulation of 3-adrenergic receptors in adipose tissue, increased lipolysis and fatty acid oxidation without activation of the hGH receptor (no IGF-1 increase) Phase 2b clinical trial (2007, 300 patients): weight reduction ~2.8 kg vs placebo over 12 weeks FDA status: NDI rejection (2014) as a dietary supplement
Reduction of Abdominal and Visceral Fat : Animal and early human models have demonstrated a preferential reduction of abdominal fat following subcutaneous administration of AOD-9604
Pathway-level interest: Used to investigate mechanisms involved in cellular energy balance and lipid handling in controlled models
NAD+ precursors are studied for supplying metabolic substrates